HK1035665A1 - Therapeutic compositions (II) - Google Patents

Therapeutic compositions (II)

Info

Publication number
HK1035665A1
HK1035665A1 HK01106060A HK01106060A HK1035665A1 HK 1035665 A1 HK1035665 A1 HK 1035665A1 HK 01106060 A HK01106060 A HK 01106060A HK 01106060 A HK01106060 A HK 01106060A HK 1035665 A1 HK1035665 A1 HK 1035665A1
Authority
HK
Hong Kong
Prior art keywords
patient
physiologically acceptable
therapeutic compositions
acceptable ketosis
ketosis
Prior art date
Application number
HK01106060A
Other languages
English (en)
Inventor
Richard L Veech
Original Assignee
Btg Int Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Btg Int Ltd filed Critical Btg Int Ltd
Publication of HK1035665A1 publication Critical patent/HK1035665A1/xx

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D323/00—Heterocyclic compounds containing more than two oxygen atoms as the only ring hetero atoms
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P21/00—Drugs for disorders of the muscular or neuromuscular system
    • A61P21/04—Drugs for disorders of the muscular or neuromuscular system for myasthenia gravis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/08—Antiepileptics; Anticonvulsants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A61P25/16—Anti-Parkinson drugs
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Medicinal Chemistry (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Biomedical Technology (AREA)
  • Diabetes (AREA)
  • Hospice & Palliative Care (AREA)
  • Psychiatry (AREA)
  • Vascular Medicine (AREA)
  • Cardiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Emergency Medicine (AREA)
  • Endocrinology (AREA)
  • Hematology (AREA)
  • Obesity (AREA)
  • Urology & Nephrology (AREA)
  • Pain & Pain Management (AREA)
  • Psychology (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Epidemiology (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Heterocyclic Compounds That Contain Two Or More Ring Oxygen Atoms (AREA)
  • Polyesters Or Polycarbonates (AREA)
  • Addition Polymer Or Copolymer, Post-Treatments, Or Chemical Modifications (AREA)
HK01106060A 1998-09-15 2001-08-28 Therapeutic compositions (II) HK1035665A1 (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US10037198P 1998-09-15 1998-09-15
PCT/US1999/021015 WO2000015216A1 (en) 1998-09-15 1999-09-15 Therapeutic compositions (ii)

Publications (1)

Publication Number Publication Date
HK1035665A1 true HK1035665A1 (en) 2001-12-07

Family

ID=22279402

Family Applications (1)

Application Number Title Priority Date Filing Date
HK01106060A HK1035665A1 (en) 1998-09-15 2001-08-28 Therapeutic compositions (II)

Country Status (18)

Country Link
US (2) US20010014696A1 (xx)
EP (1) EP1123094B1 (xx)
JP (1) JP2002524506A (xx)
KR (1) KR100805490B1 (xx)
CN (1) CN1273129C (xx)
AT (1) ATE359069T1 (xx)
AU (1) AU767238B2 (xx)
BR (1) BR9913680A (xx)
CA (1) CA2339941A1 (xx)
DE (1) DE69935799T2 (xx)
DK (1) DK1123094T3 (xx)
ES (1) ES2283133T3 (xx)
HK (1) HK1035665A1 (xx)
NZ (1) NZ509739A (xx)
PT (1) PT1123094E (xx)
RU (1) RU2242227C2 (xx)
WO (1) WO2000015216A1 (xx)
ZA (1) ZA200101260B (xx)

Families Citing this family (64)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6835750B1 (en) 2000-05-01 2004-12-28 Accera, Inc. Use of medium chain triglycerides for the treatment and prevention of alzheimer's disease and other diseases resulting from reduced neuronal metabolism II
ES2323940T3 (es) * 2000-05-01 2009-07-28 Accera, Inc. Uso de trigliceridos de cadena media para el tratamiento y prevencion de la enfermedad de alzheimer.
WO2004108740A2 (en) 2003-06-03 2004-12-16 The Government Of The United States Of America As Represented By The Secretary Of The Department Of Health And Human Services Nutritional supplements and therapeutic compositions comprising (r)-3-hydroxybutyrate derivatives
US20060275253A1 (en) * 2003-09-01 2006-12-07 Kazunari Ushida Beta hydroxy short to medium chain fatty acid polymer
US7132221B2 (en) * 2003-09-12 2006-11-07 Headway Technologies, Inc. Method to print photoresist lines with negative sidewalls
GB0410266D0 (en) * 2004-05-07 2004-06-09 Ketocytonyx Inc Treatment of apoptosis
GB0420856D0 (en) * 2004-09-20 2004-10-20 Ketocytonyx Inc Cns modulators
EP1778615A4 (en) 2004-07-20 2010-01-06 Btg Int Ltd OLIGOMERE KETONE COMPOUNDS
WO2006034361A2 (en) * 2004-09-21 2006-03-30 Ketocytonyx Inc. Dopaminergic mimetics
GB0427145D0 (en) * 2004-12-10 2005-01-12 Ketocytonyx Inc Compositions for use in surgery
US20070135376A1 (en) 2005-06-20 2007-06-14 Accera, Inc. Method to reduce oxidative damage and improve mitochondrial efficiency
HUE040002T2 (hu) 2006-04-03 2019-02-28 Accera Inc Ketogén vegyületek alkalmazása korfüggõ memóriazavar kezelésére
US7807718B2 (en) * 2006-06-30 2010-10-05 Sami A. Hashim Glyceride esters for the treatment of diseases associated with reduced neuronal metabolism of glucose
US8758740B2 (en) 2007-03-30 2014-06-24 Earthus, Inc Composition for promoting ketone body production
BRPI0811052A2 (pt) * 2007-04-12 2015-01-27 Univ Minnesota Composições de proteção de isquemia/reperfusão e métodos de uso.
CN101293831B (zh) * 2007-04-27 2013-09-18 汕头大学 3-羟基脂肪酸及其衍生物在制备钙离子通道调节剂中的用途
PT2650380E (pt) 2007-07-31 2016-01-14 Accera Inc Utilização de testagem genómica e compostos cetogénicos para o tratamento de função cognitiva reduzida
EP2214481B1 (en) 2007-10-15 2019-05-01 United Animal Health, Inc. Method for increasing performance of offspring
TR201908522T4 (tr) 2008-01-04 2019-07-22 The Government Of The U S A As Represented By The Secretary Dept Of Health And Human Services Kan lipidi düşürücü maddeler olarak keton gövdeleri ve keton gövde esterleri.
US8105809B2 (en) 2008-07-03 2012-01-31 Accera, Inc. Enzymatic synthesis of acetoacetate esters and derivatives
WO2010003114A1 (en) 2008-07-03 2010-01-07 Neuera Pharmaceuticals, Inc. Monoglyceride of acetoacetate and derivatives for the treatment of neurological disorders
US8642654B2 (en) 2009-04-16 2014-02-04 Isis Innovation Limited Hydroxybutyrate ester and medical use thereof
AU2010207597A1 (en) 2009-01-24 2011-08-18 Phytopharm Plc Treatment of neurotrophic factor mediated disorders
CN106146591B (zh) * 2010-01-08 2020-07-31 Ionis制药公司 血管生成素样3表达的调节
GB201002983D0 (en) 2010-02-22 2010-04-07 Tdeltas Ltd Nutritinal composition
CA2805693A1 (en) 2010-07-20 2012-01-26 Phytopharm Plc Treatment of l-dopa, dopamine agonist and/or dopamine enhancer induced disorders
AU2013337308B2 (en) 2012-11-05 2018-06-21 Tdeltas Ketone bodies to protect tissues from damage by ionizing radiation
GB201304467D0 (en) 2013-03-12 2013-04-24 Tdeltas Ltd Compound for use in protecting skin
BR112015023334B1 (pt) 2013-03-14 2021-05-18 Government Of The Usa, As Represented By The Secretary, Department Of Health And Human Services processo para produção de (r)-3hidroxibutil (r)-3-hidroxibutirato
CA2902603C (en) 2013-03-19 2021-03-02 University Of South Florida Compositions and methods for producing elevated and sustained ketosis
US10973792B2 (en) 2019-02-13 2021-04-13 Axcess Global Sciences, Llc Racemic beta-hydroxybutyrate mixed salt-acid compositions and methods of use
US11185518B2 (en) 2017-12-19 2021-11-30 Axcess Global Sciences, Llc S-beta-hydroxybutyrate compounds and compositions enriched with S-enantiomer
US10736861B2 (en) 2016-03-11 2020-08-11 Axcess Global Sciences, Llc Mixed salt compositions for producing elevated and sustained ketosis
US11241403B2 (en) 2016-03-11 2022-02-08 Axcess Global Sciences, Llc Beta-hydroxybutyrate mixed salt compositions and methods of use
US10596130B2 (en) 2017-12-19 2020-03-24 Axcess Global Sciences, Llc Non-racemic beta-hydroxybutyrate compounds and compositions enriched with the S-enantiomer and methods of use
US11103470B2 (en) 2017-11-22 2021-08-31 Axcess Global Sciences, Llc Non-racemic beta-hydroxybutyrate compounds and compositions enriched with the R-enantiomer and methods of use
US10292952B2 (en) 2016-03-11 2019-05-21 Axcess Global Sciences, Llc Mixed salt compositions for maintaining or restoring electrolyte balance while producing elevated and sustained ketosis
US10596129B2 (en) 2017-11-22 2020-03-24 Axcess Global Sciences, Llc Non-racemic beta-hydroxybutyrate compounds and compositions enriched with the R-enantiomer and methods of use
US10245242B1 (en) 2017-11-22 2019-04-02 Axcess Global Sciences, Llc Non-racemic beta-hydroxybutyrate compounds and compositions enriched with the R-enantiomer and methods of use
US10596131B2 (en) 2017-11-22 2020-03-24 Axcess Global Sciences, Llc Non-racemic beta-hydroxybutyrate compounds and compositions enriched with the R-enantiomer and methods of use
US10245243B1 (en) 2017-12-19 2019-04-02 Axcess Global Sciences, Llc Non-racemic beta-hydroxybutyrate compounds and compositions enriched with the S-enantiomer and methods of use
US10973786B2 (en) 2016-03-11 2021-04-13 Axcess Global Sciences, Llc R-beta-hydroxybutyrate, S-beta-hydroxybutyrate, and RS-beta-hydroxybutyrate mixed salt compositions
US11026929B2 (en) 2016-04-19 2021-06-08 Keto Patent Group, Inc. Administration of berberine metabolites
US20180057846A1 (en) 2016-08-30 2018-03-01 KetoneAid Inc. Partially buffered free acid and/or ketone blend for rapid onset ketosis and metabolic therapy
US10307398B2 (en) 2016-09-20 2019-06-04 Regents Of The University Of Minnesota Resuscitation composition and methods of making and using
EP4245368A3 (en) 2016-12-21 2024-01-03 Universitäts-kinderspital Beider Basel Migraine prevention and treatment
KR20190099469A (ko) * 2016-12-23 2019-08-27 카트호리이케 유니버시타이트 로이펜 중환자 치료의 처치에서 사용하기 위한 단독으로의 또는 조합으로의 3-히드록시부티레이트
US10376528B2 (en) 2017-03-10 2019-08-13 Tecton Group, Llc Composition comprising ketone body and nicotinamide adenine dinucleotide modulator and methyl donor
US11760963B2 (en) 2017-08-23 2023-09-19 KetoneAid Inc. Ketogenic beer and alcoholic beverage mixture containing non-racemic ethyl 3-hydroxybutyrate and/or 1,3 butanediol
US11202769B2 (en) 2017-11-22 2021-12-21 Axcess Global Sciences, Llc Ketone body esters of s-beta-hydroxybutyrate and/or s-1,3-butanediol for modifying metabolic function
US10925843B2 (en) 2018-04-18 2021-02-23 Axcess Global Sciences, Llc Compositions and methods for keto stacking with beta-hydroxybutyrate and acetoacetate
US11944598B2 (en) 2017-12-19 2024-04-02 Axcess Global Sciences, Llc Compositions containing s-beta-hydroxybutyrate or non-racemic mixtures enriched with the s-enatiomer
GB2572185A (en) * 2018-03-21 2019-09-25 Chain Biotechnology Ltd Pharmaceutical compositions
US11129802B2 (en) 2018-08-27 2021-09-28 Axcess Global Sciences, Llc Compositions and methods for delivering cannabidiol and ketone bodies
US10512615B1 (en) 2018-08-27 2019-12-24 Axcess Global Sciences, Llc Compositions and methods for delivering cannabidiol and ketone bodies
US10980772B2 (en) 2018-08-27 2021-04-20 Axcess Global Sciences, Llc Compositions and methods for delivering tetrahydrocannabinol and ketone bodies
US11241401B2 (en) 2020-02-06 2022-02-08 Axcess Global Sciences, Llc Enantiomerically pure r-beta-hydroxybutyrate mixed salt-acid compositions
US11419836B2 (en) 2019-02-13 2022-08-23 Axcess Global Sciences, Llc Racemic and near racemic beta-hydroxybutyrate mixed salt-acid compositions
US11806324B2 (en) 2018-04-18 2023-11-07 Axcess Global Sciences, Llc Beta-hydroxybutyric acid compositions and methods for oral delivery of ketone bodies
US11950616B2 (en) 2019-06-21 2024-04-09 Axcess Global Sciences, Llc Non-vasoconstricting energy-promoting compositions containing ketone bodies
US11033553B2 (en) 2019-06-21 2021-06-15 Axcess Global Sciences, Llc Non-vasoconstricting energy-promoting compositions containing ketone bodies
IT201900022854A1 (it) * 2019-12-03 2021-06-03 Dr Schaer S P A Formulazione alimentare e prodotto alimentare da forno per la gestione della dieta chetogenica
AU2022315496A1 (en) 2021-07-17 2023-12-07 Ketoswiss Ag Combination of a ketone body or ketogenic compound with an analgesic or antioxidant
US11969430B1 (en) 2023-03-10 2024-04-30 Axcess Global Sciences, Llc Compositions containing paraxanthine and beta-hydroxybutyrate or precursor for increasing neurological and physiological performance

Family Cites Families (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP0522422A3 (en) * 1991-07-01 1993-03-17 Mitsubishi Kasei Corporation Process for producing a biodegradable polymer
JP2885261B2 (ja) * 1993-05-17 1999-04-19 三菱瓦斯化学株式会社 ３−ヒドロキシ酪酸のオリゴマー及びその塩からなる輸液製剤
JP4598203B2 (ja) 1995-12-01 2010-12-15 ビーティージー・インターナショナル・リミテッド 脳機能改善剤
US6323237B1 (en) * 1997-03-17 2001-11-27 Btg International Limited Therapeutic compositions
KR100839689B1 (ko) * 1997-03-17 2008-06-18 비티지 인터내셔널 리미티드 치료용 조성물
WO1999034687A1 (en) * 1998-01-07 1999-07-15 Metabolix, Inc. Animal nutrition compositions
AU755348B2 (en) * 1998-07-22 2002-12-12 Cj Cheiljedang Corporation Nutritional and therapeutic uses of 3-hydroxyalkanoate oligomers

Also Published As

Publication number Publication date
AU5921299A (en) 2000-04-03
KR100805490B1 (ko) 2008-02-20
ZA200101260B (en) 2001-08-16
NZ509739A (en) 2003-10-31
BR9913680A (pt) 2001-06-05
DK1123094T3 (da) 2007-08-20
AU767238B2 (en) 2003-11-06
ES2283133T3 (es) 2007-10-16
EP1123094B1 (en) 2007-04-11
DE69935799T2 (de) 2007-12-27
US7351736B2 (en) 2008-04-01
WO2000015216A1 (en) 2000-03-23
KR20010079830A (ko) 2001-08-22
CA2339941A1 (en) 2000-03-23
EP1123094A1 (en) 2001-08-16
CN1273129C (zh) 2006-09-06
EP1123094A4 (en) 2001-10-04
US20010014696A1 (en) 2001-08-16
RU2242227C2 (ru) 2004-12-20
PT1123094E (pt) 2007-06-28
JP2002524506A (ja) 2002-08-06
US20040171671A1 (en) 2004-09-02
ATE359069T1 (de) 2007-05-15
CN1316902A (zh) 2001-10-10
DE69935799D1 (de) 2007-05-24

Similar Documents

Publication Publication Date Title
HK1035665A1 (en) Therapeutic compositions (II)
BE2018C038I2 (xx)
IL133585A0 (en) Soluble prodrugs of paclitaxel
MY130157A (en) Method of use for inhibiting bone loss and lowering serum cholesterol
GR3007251T3 (xx)
CA2391539A1 (en) Use of poly(diallylamine) polymers
RU94045155A (ru) Способы ингибирования болезни альцгеймера
RU2001110097A (ru) Терапевтические композиции (ii)
EP0777484A4 (en) INTRAVENOUS ALENDRONATE FORMULATIONS
MX9805588A (es) Administracion oral de cantidades efectivas de formas de acido hialuronico.
HU9303000D0 (en) Aryl-morpholine-derivatives and pharmaceutical compositions containing it and process for production thereof
NZ303993A (en) Pharmaceutical compositions containing aminotetralin derivatives for treating cardiac disorders
DE3688787D1 (de) Herstellung eines arzneimittels gegen arthritis und rheumatismus.
HUT73500A (en) Use of benzydamine for producing pharmaceutical compositions for treatment of pathological conditions caused by tnf
Kaldor et al. Enhancement of methyldopa metabolism with barbiturate
SU1475668A1 (ru) Способ лечени функциональных поражений лицевого нерва
UA10301A (uk) Спосіб лікуваhhя раку шлуhку
SU944583A1 (ru) Способ реабилитации травматических поражений мышц
UA30251A (uk) Спосіб лікування гіпертонії сфінктера одді у хворих на хронічний безкам'яний холецистит при поєднанні з підвищенням тонусу симпатичної нервової системи
UA30912A (uk) Спосіб терапії хворих на хронічний обструктивний бронхіт
UA15281A (uk) Спосіб лікуваhhя хроhічhої ішемічhої хвороби серця
UA30184A (uk) Спосіб рефлексотерапії хворих з віддаленими наслідками черепно-мозкової травми
UA28922A (uk) Спосіб лікування респіраторного дистрес-синдрому дорослих
UA7190A (uk) Спосіб лікування запально-гнійних захворювань легень
RU2000106699A (ru) Способ лечения заболеваний методом настройки биоритмов организма

Legal Events

Date Code Title Description
PC Patent ceased (i.e. patent has lapsed due to the failure to pay the renewal fee)

Effective date: 20110915